Diligence memo · auto-generated · as of July 3, 2026
Bond Biosciences, Inc.
Bond Biosciences, Inc. looks under-valued against its niche peers and is quiet on financing cadence.
Businessfiled
Bond Biosciences, Inc. operates in Biotech / Pharma, based in Parkville.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Bond Biosciences, Inc. has raised $17M in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $6.8M on 2021-12-17.
Most recent recorded round closed around 2024-08-22.
Valuation (modeled)modeled
Provath models Bond Biosciences, Inc. at approximately $22M (range $5.0M–$46M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.56× the median modeled value of Series A Biotech / Pharma companies in 2022–2024 (21 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 6 months.
Last raise 22 mo ago; this sector typically re-raises about every 15 months.
Slightly overdue versus sector cadence.
The last round was 1.5× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 71% of Biotech / Pharma peers (227 compared).
Modeled value ranks above 44% of those peers.
Closest niche peers: Laxmi Therapeutic Devices, Inc., Accipiter Biosciences Inc., Nanospectra Biosciences Inc, Ten Bay Bio, Inc., Genomic Life, Inc..
Peoplefiled
4 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.